Abstract: Hepatocellular carcinoma (HCC) is the seventh most common malignancy worldwide. HCC meets all the criteria established by the World Health Organization for performing surveillance on those at-risk for developing cancer. Although there are consensus guidelines in the United States, Europe, and Asia for HCC surveillance, it is unclear if these guidelines are regularly implemented in routine practice to optimize real-life clinical outcomes. We reviewed the current literature on the adherence to current HCC practice guidelines by the American Association for the Study of Liver Diseases (2009), the European Association for the Study of the Liver (2012), and the Asia Pacific Association for the Study of the Liver (2010) for screening/surveillance and outcomes of optimal versus poor adherence. We performed PubMed search for relevant articles regarding HCC surveillance and screening worldwide. Currently, HCC screening is underutilized to a large extent. In most studies, the adherence to HCC screening and surveillance is suboptimal. Various patient, provider, and health care system factors may have all contributed to such nonadherence. Strategies to improve HCC screening and surveillance are urgently needed for early HCC detection and improved survival of HCC patients. Further research is needed to elucidate the various medical and/or cultural knowledge, belief, and practice patterns that can lead to barriers to HCC screening and surveillance at both patient and provider levels. These data will help focus and target advocacy and educational efforts to improve HCC surveillance at all levels: patients, providers, and health care system/government.
H epatocellular carcinoma (HCC) is the seventh most common malignancy worldwide, and the third most common cause of cancer-related death, after lung and stomach cancer. The World Health Organization (WHO) defines screening as the presumptive identification of unrecognized disease or defects by means of tests, examinations, or other procedures that can be applied rapidly. 1 HCC screening is an application of diagnostic tests in patients at risk for HCC, but in whom there are no a priori reasons to suspect that HCC is present. HCC surveillance is the serial application of screening tests to detect the presence of HCC in these high-risk populations before it becomes clinically suspected or evident. HCC is a disease that meets all the criteria established by WHO for the performance of surveillance in those at-risk for developing cancer. Other screening programs, such as those for breast, cervical, and colorectal cancer, have also been advocated by WHO, and have been effectively implemented, and their utilization has demonstrated great effectiveness and practicability. [2] [3] [4] The rationale for conducting HCC surveillance is that regular screening of at-risk asymptomatic patients may detect tumors at an early stage when potentially curative treatment can be offered. Patients with early-stage HCC diagnosed by routine surveillance can achieve a much higher 5-year survival of 70% compared with <6 months as seen in advanced-stage HCC and <3 months in endstage HCC. [5] [6] [7] In recent years, several major liver disease societies in the United States, Europe, and Asia have all reached a consensus and published guidelines for HCC screening and surveillance.
In this review, we will summarize the major current practice guidelines and review the adherence to HCC screening and surveillance guidelines in routine clinical practice. Understanding the gaps in HCC surveillance and factors affecting it will help improve clinical practice and ultimately the clinical outcomes of patients who are at risk for HCC.
HCC EPIDEMIOLOGY
The International Agency for Research on Cancer ranks liver cancer as the seventh most common cancer overall and fifth most common cancer in men (554,000 cases, 7.5% of all cancers) and the ninth most common in women (228,000 cases, 3.4% of all cancers). HCC is responsible for nearly 746,000 deaths globally (9.1% of the total) in 2012. 8 HCC is largely a problem of the less developed regions where 83% (50% in China alone) of the estimated 782,000 new HCC cases occurred in 2012 (Table 1) . 8 In addition, in recent decades, HCC incidence and HCC-related deaths have been rising (Table 1) , which occurred not only in developing but also in the developed world. Table 2 shows the HCC upward trend in North America with new HCC cases rising from 16,600 to 24, 200 and HCC-related deaths from 13,700 to 18,400 in men between 2008 and 2012. 8, 11 By 2020, the number of HCC new cases may reach 27,000 in the United States. 11 Most HCC cases arise in Eastern Asia and South Eastern Asia where the risk rate is considered high with age standardized rate (ASR) of over 20 per 100,000 personyears. African countries (such as Benin, Mauritania) are considered to be areas with moderately high-risk rate with ASR of 11 to 20 per 100,000 person-years. Spain, the United States, and Austria are among the intermediate-risk rate countries with ASR of 5 to 10 per 100,000 personyears. Eastern Africa, Central and Eastern Europe, Northern Europe, and South Central Asia have lower HCC ASR of <5.0 per 100,000 person-years (Table 3) . 8 The prognosis for HCC is very poor with overall ratio of mortality to incidence of 0.95, indicating that the fatality (or lethality) rate of HCC is very high with the number of patients dying of HCC almost similar to the number of new HCC cases during the same time period. 8 Approximately 90% of HCC cases are associated with a known underlying risk factor. Table 4 shows the most frequent factors that include hepatitis B virus (HBV), hepatitis C virus (HCV), cirrhosis of any causes, and alcohol abuse. Both HBV and HCV infections increase the HCC risk by approximately 20 fold. 17 About one-third of all HCC occurring in the world are attributable to HCV or HBV. 18 In the United States, Latin America, Japan, and several regions of Europe, HCV is the leading cause of HCC. In Africa, and many parts of Eastern Europe, HBV is the dominant cause of HCC, far outweighing the impact of HCV. 19 In Asia, the proportion of HBsAg-positive HCC cases is >50% in China, Taiwan, Korea, Thailand, Vietnam, and Turkey. 20 Table 5 shows the annual HCC incidence by different disease etiologies. Regardless the etiology of underlying liver disease, patients with cirrhosis have the highest risk of developing HCC comparing to those without. Cirrhosis underlies approximately 80% to 90% of HCC cases worldwide, whereas only 10% to 20% HCC develop in patients without cirrhosis with most of these occurring in patients with chronic hepatitis B (CHB). 21, 71 Patients with CHB or chronic hepatitis C have higher HCC risk than those without viral infection (Table 5) .
HCC rarely occurs before the age of 40 years, except for those caused by CHB. The mean ages of HCC diagnosis are 55 to 59 years in China and 63 to 65 years in Europe and North America. In low-risk populations, the highest HCC incidence is among individuals 75 years or older. HCC is predominant among men with the male to female ratio of 3:1 in areas of high incidence. 72 
RATIONALE IN HCC SURVEILLANCE
The new WHO criteria for cancer surveillance programs are listed in Table 6 . According to these criteria, WHO has advised screening for breast, cervical, and colorectal cancers. The early detection of these cancers greatly increases the chances for successful treatment and a decrease in mortality. [2] [3] [4] HCC meets all of the WHO criteria for establishing a similar cancer surveillance program (Table 6 ).
The fundamental aim of cancer surveillance is a reduction in disease-related mortality. One randomized controlled trial of surveillance versus no surveillance in 18,816 HBV patients in China demonstrated a survival benefit with a strategy of twiceyearly surveillance with alpha-fetoprotein (AFP) and ultrasound. In subjects in the surveillance group, HCC-related mortality was reduced by 37%. 73 Several nonrandomized cohort studies have also concluded that surveillance has detected HCC in earlier stages and led to better outcomes than found in the control group. 14, [74] [75] [76] In a study by Llovet et al, 77 patients with early HCC achieved 5-year survival rates of 70% with resection or transplantation, whereas those with advanced HCC had a median survival of <1 year. A higher proportion (45.6%) of patients in the surveillance group also received curative treatment options, including hepatic tumor resection and local ablative therapy, than those (22.7%) in the nonsurveillance group. Comparing surveillance and nonsurveillance groups, the median survival time was 48.1 and 12.7 months, respectively. The 3-year survival rate of the surveillance group was significantly superior to that of the nonsurveillance group (59.1% vs. 29.3%, P < 0.001). 78 In Japan, active and successful screening and surveillance programs have resulted in a higher proportion of tumors identified at early stages when curative treatments can be applied. 79 
CURRENT CONSENSUS
A workshop on "Screening for HCC" was first held in Alaska in 1991, addressing HCC screening for patients with CHB. A decade later in 2001, the European Association for the Study of the Liver (EASL) issued its influential HCC guideline recommending HCC screening for patients with cirrhosis. Since then, several more guidelines have been published and updated by different professional associations or countries. 6, 19, [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] The American Association for the Study of Liver Diseases (AASLD), EASL, and the Asian Pacific Association for the Study of the Liver (APASL) guidelines on HCC have heavily influenced the practices in North America, Europe, Asia, and other regions in the world. Table 7 shows the most recent HCC screening and surveillance recommendations from these liver societies.
These guidelines recommend screening patients who are at-risk for HCC, including patients with cirrhosis of any causes and certain groups of patients with CHB but without established cirrhosis. There are some differences in the guidelines regarding screening methods, particularly regarding surveillance intervals. The AASLD HCC 2005 guideline recommended ultrasound with or without AFP at 6-to 12-month intervals in at-risk patients. With the emergence of new evidence, the AASLD HCC 2010 guideline recommended ultrasound at 6-month intervals, and the EASL 2012 guideline agreed with this view. In Asia, however, where the etiology of HCC generally differs from the West, the APASL 2010 guideline recommended ultrasound with AFP at 6-month intervals. The Japanese protocol was even more stringent, suggesting ultrasound and AFP/antagonist-II (PIVKA-II)/AFP lectin fraction (AFP-L3) at 6-month intervals for high-risk patients that were defined as those with either CHB, chronic hepatitis C, or nonviral cirrhosis. For super high-risk patients that were defined as those with HBV or HCV-related cirrhosis, ultrasound and AFP/PIVKA-II/AFP-L3 were recommended at intervals of every 3 to 4 months, in addition to computed tomography or magnetic resonance imaging/ ethoxybenzyl-magnetic resonance imaging at intervals of every 6 to 12 months. 89 
ADHERENCE TO HCC SCREENING AND SURVEILLANCE
Despite these guidelines and improvements in diagnosis and treatment since 2001, death from HCC is still dismally high. As mentioned above, HCC incidence and mortality have increased from 2002 to 2012 and beyond (Table 1) . 8, 9, 11 Poor adherence to screening maybe one of the major responsible causes and in the remainder of this review, we reviewed recent studies on adherence to HCC screening and surveillance (Tables 8-11 ).
The study regions reviewed include Asia (Japan, China, Hong Kong, Taiwan, Korea), Europe (Italy, Spain, France, Belgium), Australia, and North America (USA, Canada). In general, Japan has higher compliance to HCC surveillance, even in the early studies before 2001. 118, 119, [121] [122] Japan is one of the few countries that carried out an HCC national screening program, which covered the expense to the patient and used a more stringent guideline (more screening tests and shorter screening intervals). The USA screening adherence rates varied from 12.0% to 78.8%. 104, 106 The discrepancy may be due to the enrolled patients coming from different ethnicities, different level of care centers, and different health care insurance systems. [99] [100] [101] 104, 131 In the above studies, study design can be classified as either a retrospective or a prospective HCC screening or surveillance study. In the prospective studies, adherence rates appear higher and a large proportion of the patients were enrolled in advanced centers (high-level hospitals, more academic affiliations). In the study by Singal et al, 92 the author pointed out that study site was a strong predictor of consistent surveillance. In addition, research physicians may be more conscientious about follow-up of enrolled patients. In the 16-year community-based prospective HCC screening study by McMahon et al, 25 the researchers sent reminder letters every 6 months to both patients and primary care physicians to improve compliance. Thus, at the 12-month surveillance interval, adherence was found to be quite high at 61% to 79%, although these patients came from 126 communities, some of which were isolated villages without road access. The study performed by Aberra and colleagues showed an even higher adherence rate up to 93.1%. These researchers implemented quality improvement measures to increase the rate of HCC surveillance among patients with cirrhosis in a tertiary care facility. Implementation of quality improvement measures incorporating automatic reminders of surveillance status for providers significantly increased the adherence rate. 91 These adherence data are encouraging, and the procedure is worth duplicating. In contrast, the retrospective studies collected information from databases and generally showed lower adherence rates. 99, 101, 103 In terms of adherence to effectiveness of HCC screening and surveillance, results from these retrospective studies may be closer to real-life clinical practice, and they clearly show the reality of low adherence. Tables 8-11 show the reported low rates of HCC surveillance in routine clinical practice. Some of the studies of at-risk populations were carried out before published guidelines, and consequently, screening efforts largely focused on patients with cirrhosis or with viral hepatitis. Generally, patients with cirrhosis had more regular surveillance, 74, 109, 118 which may be explained by both physician and patient awareness of the seriousness of cirrhosis. 131 In contrast, both patients and physicians may under estimate the importance of surveillance in patients with viral hepatitis but without cirrhosis. Furthermore, Stravitz et al 74 found that nearly half of patients were even unaware of their viral infection and/or cirrhosis. At-risk patients are often underdiagnosed for both viral infection and cirrhosis. 101 Davila and colleagues found that <20% of cirrhotic patients who developed HCC had received regular surveillance. 108 Screening methods adopted in these later studies were generally similar with present guidelines, using imaging and AFP as the preferred screening method. The screening intervals were usually at 6 or 12 months. 5, 90 Women were more likely to receive regular surveillance. 108, 132 Those patients who visited a specialist (gastroenterologist or hepatologist) rather than a primary care provider also tended to have higher surveillance rates. 99, 108, 111, 131, 133 In addition, Wong et al 109 found that patients who had more clinical visits received more regular surveillance than those who had less visits. Fewer specialist visits and less access to academic hospitals may also reduce adherence rates; and Robotin et al 134 in Australia reported that optimal adherence to screening guidelines could be achieved if the government offered approximately 750 additional specialist consultations or approximately 25 additional consultations per provider per year. Because of the limited availability of subspecialty care, only 20% to 40% of patients with cirrhosis can be referred to and followed by gastroenterologists/hepatologists. 108 Studies have also shown that even patients with cirrhosis who were aware of their disease did not adhere to HCC surveillance, thus failing to detect HCC in its earliest stage. 76, 108 Survey studies showed that 90% of primary care providers believe that HCC surveillance is their responsibility but only 45% reported that they performed HCC surveillance in their patients with cirrhosis, [135] [136] [137] and that HCC surveillance does occur more frequently when patients are followed by gastroenterologists/ hepatologists than when they are only followed in primary care clinics. 138 Unfortunately, even among patients who were closely followed by expert hepatologists at academic centers, only two-thirds had consistent HCC surveillance. 92 Socioeconomic factors are also important in adherence to HCC screening and surveillance with patients living in urban areas and those with higher incomes more likely to receive regular surveillance, 108 whereas lack of insurance coverage was a predictor for inconsistent HCC screening. 113 Fleming et al 139 reported that highly educated, white-collar cancer survivors who were provided comprehensive private health insurance tend to have had better cancer screening practices. Clarke et al 140 consider that the decline of insurance coverage rates is a contributing factor to cancer screening adherence decline over the research period. In Davila et al (2007) 112 Housto another study with a large nationally representative population sample, increased adherence to preventive care grew in step with the gain of health insurance coverage for screening of colorectal, prostate, breast, and cervical cancer, suggesting that health insurance coverage can reduce financial barriers and improve access to preventive care. 141 Lastly, lack of a recall policy and delayed evaluation of abnormal screening tests also reduced the effectiveness of HCC screening. Singal et al 92 found that in nearly onefourth of patients, the follow-up of abnormal screening tests was delayed >6 months, giving the tumor a chance to double in size. The survey of Sharma et al 142 showed that not all gastroenterologists know how to appropriately manage abnormal result of HCC screening tests.
CONCLUSIONS
Guidelines recommend that HCC surveillance for highrisk patients be carried out to detect HCC at an early stage, when treatments can be most effectively applied. In real-life practice, we have not reached the WHO screening goal to reduce cancer mortality and morbidity. HCC surveillance is poorly adhered to and is related to a number of factors. HCC screening/surveillance is a complex process, with failure at every step in the process contributing to a gap between efficacy and effectiveness, 143 and many of these should be modified.
First, additional education of both patients and providers is essential. Education should be for both HCC screening and surveillance as well as screening and diagnosis of underlying liver diseases, as all current HCC guidelines rely on identification of at-risk populations who would benefit from HCC surveillance. 144 Provider education should include primary care practitioners who have the most encounters with patients to first diagnose at-risk patients. We can take the colorectal cancer screening tactic to optimize the HCC screening protocol. Professional organizations or grants may offer resources for patients and health professionals as following: printed materials (fact sheets, brochures, and posters); television and radio public service announcements; digital media initiative (Digital Display advertising, Screening for HCC web page, online continuing medical education courses); and grants for relevant research.
Second, advocacy regarding the importance of HCC surveillance and its current underutilization should be made to policy makers, especially in areas with high HCC incidence where a national screening program may be needed. Even at local and regional level, implementation of regular clinical visits and recall policy are important in improving HCC surveillance adherence rates and appropriate evaluation of patients with abnormal screening tests. More health care investment to increase access to specialist care and frequency of clinical visits for the high-risk populations may also be helpful.
Thirdly, new reminder and recall system was applied to improve the adherence and outcome. A personalized automated messaging system that can send automated calls and/or text messages to inform patients they were due for repeat HCC screening may improve adherence to HCC screening. At least 1 prior study has shown that clinical reminder system can increase adherence to HCC surveillance in patients with cirrhosis. 145 
